To further evaluate TIGIT-mediated tumor accumulation and overcome peripheral antigen sink, we repeated 89Zr-αTIGIT PET studies using a lower molar activity (higher antibody dose; 100 μg) and blocking dose (625 μg unconjugated anti-TIGIT) in mice with 1-week established GL261 tumors (Fig. 4B, Supplementary Figure S3A, S3B). Here, TIGIT is linked to neoplasm.